PORCINE HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS (pHEV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Minor: Low prevalence, typically non-lethal infection with recovery very likely; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Porcine hemagglutinating encephalomyelitis virus (pHEV) is a betacoronavirus first isolated from pigs with encephalomyelitis in Canada in 1962. The virus causes two distinct clinical syndromes in susceptible piglets under 3-4 weeks of age: vomiting and wasting disease (VWD) characterized by persistent vomiting, constipation, and progressive emaciation; and acute encephalomyelitis with motor disorders including tremors, paddling, and paralysis. A respiratory variant (rvpHEV) associated with influenza-like respiratory illness has been identified more recently, expanding the recognized disease spectrum. pHEV is endemic worldwide with remarkably high seroprevalence—surveys demonstrate approximately 53% individual pig seropositivity and 96% herd seropositivity in the United States—yet clinical disease is rare. This paradox occurs because most breeding females carry antibodies from subclinical infection and protect their offspring through maternal immunity during the vulnerable neonatal period. Clinical outbreaks occur sporadically when non-immune gilts farrow susceptible litters or when the virus is introduced into naive high-health or SPF herds lacking endemic circulation.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Pigs are the only species known to be naturally susceptible to pHEV. No human infections through food consumption have been documented despite decades of endemic global circulation and high seroprevalence in swine populations. The virus demonstrates strict host specificity for pigs with no public health significance. Pork products from seropositive pigs (essentially all commercial swine) pose no food safety concerns.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
No human pHEV infections have been reported through any route despite ubiquitous human exposure to endemic seropositive swine populations worldwide. The virus replicates in swine neural and respiratory tissues but does not infect humans through occupational contact, aerosol exposure, or any other identified pathway. Experimental infection studies demonstrate limited cross-species neurotropism in laboratory rodents (mice and rats), but this experimental susceptibility has not translated to any natural human infection risk. Occupational exposure to pHEV-infected pigs presents no infection hazard to workers.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
pHEV spreads efficiently by aerosol transmission, demonstrating similar airborne characteristics to PRCV. The virus is excreted oronasally for 8-10 days post-infection, and transmission occurs via nasal secretions, nose-to-nose contact, and aerogenically between pens and facilities. This efficient aerosol transmission route allows spread between buildings and potentially between nearby farms without requiring direct pig contact, movement of contaminated materials, or personnel traffic—fundamentally undermining conventional biosecurity measures designed around physical barriers and sanitation protocols. pHEV maintains endemic circulation in swine-dense regions by continuously infecting successive groups of pigs after weaning as maternal antibody protection wanes, perpetuating subclinical respiratory transmission through populations. Biosecurity measures effective against fomite-transmitted pathogens cannot prevent aerosol introduction of pHEV.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
pHEV diagnosis presents greater challenges than enteric coronavirus detection, though confirmation is achievable when specifically pursued. Virus isolation requires specialized cell lines (primary pig kidney cells, secondary pig thyroid cells, or the HRT-18G human rectal tumor cell line) and detection relies on identifying syncytia formation combined with hemadsorption or hemagglutination activity—less routine procedures than standard cytopathic effect observation used for other coronaviruses. Specimens must be collected from acutely diseased pigs within 2-3 days of clinical onset, as virus becomes increasingly difficult to isolate during later disease stages. RT-PCR assays targeting pHEV exist but are not as widely incorporated into routine diagnostic panels as PEDV, PDCoV, and TGEV assays. Serological tests including virus neutralization, hemagglutination inhibition, and ELISA formats exist, but interpretation is complicated by very high background seroprevalence—essentially all commercial herds are positive, making paired serology for acute diagnosis difficult. Clinical presentation (neurological signs in young piglets, persistent vomiting and wasting) is distinctive when present but requires differentiation from other neurotropic infections including Teschen-Talfan disease and pseudorabies, necessitating specific laboratory testing. Many diagnostic laboratories have limited routine experience with pHEV given the rarity of clinical submissions.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Minor: Low prevalence, typically non-lethal infection with recovery very likely
Clinical pHEV disease is rare in modern commercial swine production because endemic subclinical circulation ensures most breeding females carry protective antibodies that transfer to piglets through colostrum, preventing clinical disease during the susceptible neonatal window. Outbreaks occur only in specific circumstances: litters from non-immune gilts or young sows lacking prior exposure, or introduction into naive SPF or high-health herds that lack endemic circulation. When clinical outbreaks do occur, mortality can approach 100% in neonatally infected litters—the 2006 Argentine outbreak in a 6000-sow herd with 55% gilts and young sows caused 12.6% mortality in suckling pigs within affected farrowing units, demonstrating severe localized impact. However, such outbreaks represent isolated sporadic events affecting a tiny fraction of industry production rather than widespread losses. The vast majority of pHEV infections are subclinical respiratory events with no measurable production impact, occurring continuously as an unnoticed background phenomenon in most herds.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
pHEV is endemic worldwide and has no effect on international trade or market access. The virus is not an OIE-listed disease, and seropositivity—which characterizes essentially all commercial swine populations globally—does not trigger regulatory responses or trade restrictions. US surveys demonstrating 96% herd seroprevalence establish that pHEV-positive status is the expected baseline rather than a notifiable condition. Clinical outbreaks cause localized farm-level losses absorbed by individual operations but have no market implications, movement restrictions, or consumer awareness concerns.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
pHEV is a viral pathogen that does not carry, acquire, or disseminate antimicrobial resistance determinants. The virus contributes nothing to AMR concerns regardless of disease epidemiology or management approaches.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for pHEV. Clinical disease presentations—encephalomyelitis with neurological signs, or vomiting and wasting syndrome—are not conditions amenable to or typically treated with antimicrobial therapy. Antibiotics would only be considered for secondary bacterial complications, which are not a recognized feature of typical pHEV clinical disease. The extreme rarity of clinical outbreaks further minimizes any antimicrobial use associated with this pathogen. pHEV infection and management generate essentially zero selection pressure for antimicrobial resistance.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments exist for pHEV infection. Once clinical signs of encephalomyelitis or vomiting and wasting disease appear, the disease typically runs its course with spontaneous recovery being rare in severely affected piglets. Experimental approaches using small interfering RNAs targeting pHEV genes successfully prevented viral replication in cell culture, but these have not been tested in pigs and are not available for field application. Passive protection using specific immune serum administered to piglets shortly after birth can protect offspring from non-immune sows during outbreak situations, but this represents a prophylactic intervention in at-risk animals rather than treatment of clinical disease. Therapeutic development has not been prioritized given the rarity of clinical outbreaks and the effectiveness of natural endemic immunity in preventing disease under normal production conditions.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No commercial pHEV vaccines have been developed or marketed. The epidemiological reality that clinical disease occurs only in rare circumstances—non-immune litters or naive high-health herds—combined with the natural development of age-related resistance after 3-4 weeks of life means vaccination is not economically justified for the overwhelming majority of swine operations. Control in endemic herds relies on maintaining virus circulation so all gilts become infected and immune before their first farrowing, naturally transferring protection to their offspring. For naive SPF or isolated herds at risk of introduction, controlled deliberate exposure to establish herd immunity represents the de facto prevention strategy rather than vaccination. Commercial vaccine development has not been pursued given the extremely limited market demand for a product addressing sporadic rare outbreaks.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
pHEV has achieved ubiquitous endemic status in US and global swine populations, with surveys demonstrating approximately 96% herd seroprevalence among US breeding females. The virus spreads efficiently by aerosol transmission over distances that can span between facilities, making farm-level elimination technically impossible in any region with significant swine density—continuous airborne reinfection would occur. Endemic subclinical circulation perpetuates the virus through continuous infection of susceptible pigs after maternal antibody waning, maintaining transmission chains indefinitely within and between herds. The fundamental paradox of pHEV epidemiology further argues against eradication: widespread endemic infection actually prevents clinical disease by ensuring maternal immunity, while eliminating the virus would create immunologically naive populations at severe risk of clinical outbreaks upon reintroduction. Given the combined barriers of efficient airborne transmission, global endemic distribution, and the counterproductive consequence that eradication would increase clinical disease risk, there is neither technical feasibility nor biological rationale for pHEV eradication efforts.